Timeline milestone
CAR T Cells Turn a Patient's Immune System Into a Living Drug
From How Cancer Treatment Became Personal: From Chemotherapy to Precision Immunotherapy
-
Regulatory
CAR T Cells Turn a Patient's Immune System Into a Living Drug
The first CAR T-cell approvals genetically reprogrammed each patient's T cells to recognize a cancer marker, producing deep responses in some blood cancers.
CAR T therapy combined gene engineering, cell manufacturing and immunology in one individualized treatment. It could rescue some patients after other options failed, but severe immune reactions, neurological toxicity, cost and difficult manufacturing limited access, while most solid tumours remained resistant.
Sources & references 1 source
